High Tech Pharm Co. Ltd - Asset Resilience Ratio
High Tech Pharm Co. Ltd (106190) has an Asset Resilience Ratio of 0.77% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read debt load of High Tech Pharm Co. Ltd for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2014–2024)
This chart shows how High Tech Pharm Co. Ltd's Asset Resilience Ratio has changed over time. See 106190 net assets for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down High Tech Pharm Co. Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see market value of High Tech Pharm Co. Ltd.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 0% |
| Short-term Investments | ₩1.07 Billion | 0.77% |
| Total Liquid Assets | ₩1.07 Billion | 0.77% |
Asset Resilience Insights
- Limited Liquidity: High Tech Pharm Co. Ltd maintains only 0.77% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
High Tech Pharm Co. Ltd Industry Peers by Asset Resilience Ratio
Compare High Tech Pharm Co. Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Yabao Pharmaceutical Group Co Ltd
SHG:600351 |
Drug Manufacturers - Specialty & Generic | 0.27% |
|
Jiangsu Hengrui Medicine Co Ltd
SHG:600276 |
Drug Manufacturers - Specialty & Generic | 0.16% |
|
Sandoz Group AG
SW:SDZ |
Drug Manufacturers - Specialty & Generic | 6.43% |
|
Swedish Orphan Biovitrum AB (publ)
ST:SOBI |
Drug Manufacturers - Specialty & Generic | 1.54% |
|
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt
F:RIG2 |
Drug Manufacturers - Specialty & Generic | 0.20% |
|
Shijiazhuang Yiling Pharmaceutical Co Ltd
SHE:002603 |
Drug Manufacturers - Specialty & Generic | 6.40% |
|
Kangmei Pharmaceutical Co Ltd
SHG:600518 |
Drug Manufacturers - Specialty & Generic | 0.00% |
|
Shandong Buchang Pharmaceuticals Co Ltd
SHG:603858 |
Drug Manufacturers - Specialty & Generic | 3.47% |
Annual Asset Resilience Ratio for High Tech Pharm Co. Ltd (2014–2024)
The table below shows the annual Asset Resilience Ratio data for High Tech Pharm Co. Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 0.00% | ₩450.00 ≈ $0.30 |
₩140.09 Billion ≈ $94.94 Million |
-1.39pp |
| 2023-12-31 | 1.39% | ₩1.88 Billion ≈ $1.28 Million |
₩135.06 Billion ≈ $91.53 Million |
-4.56pp |
| 2022-12-31 | 5.96% | ₩7.87 Billion ≈ $5.34 Million |
₩132.20 Billion ≈ $89.59 Million |
-4.32pp |
| 2021-12-31 | 10.28% | ₩12.63 Billion ≈ $8.56 Million |
₩122.94 Billion ≈ $83.31 Million |
+9.47pp |
| 2020-12-31 | 0.80% | ₩1.03 Billion ≈ $699.90K |
₩128.45 Billion ≈ $87.05 Million |
-7.04pp |
| 2019-12-31 | 7.84% | ₩10.33 Billion ≈ $7.00 Million |
₩131.73 Billion ≈ $89.27 Million |
+4.86pp |
| 2018-12-31 | 2.98% | ₩3.96 Billion ≈ $2.68 Million |
₩133.00 Billion ≈ $90.13 Million |
+0.46pp |
| 2017-12-31 | 2.52% | ₩3.00 Billion ≈ $2.03 Million |
₩119.10 Billion ≈ $80.71 Million |
-5.99pp |
| 2016-12-31 | 8.51% | ₩10.06 Billion ≈ $6.82 Million |
₩118.31 Billion ≈ $80.18 Million |
-0.40pp |
| 2015-12-31 | 8.91% | ₩9.92 Billion ≈ $6.72 Million |
₩111.43 Billion ≈ $75.51 Million |
-12.24pp |
| 2014-12-31 | 21.14% | ₩22.53 Billion ≈ $15.27 Million |
₩106.60 Billion ≈ $72.24 Million |
-- |
About High Tech Pharm Co. Ltd
High Tech Pharm Co., Ltd. researches and develops, manufactures, and sells injectable carbapenem-based antibiotics worldwide. The company was incorporated in 1998 and is based in Chungju-si, South Korea.